Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 3;2(1):vdaa093. doi: 10.1093/noajnl/vdaa093

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — Established prognostic gene signature expression is driven by glioblastoma structure. (A) A survival prediction gene set demonstrates differential expression in tumor structures, with opposite expression in the IT/LE and the PAN/PNZ/HBV/MVP. Transcripts were organized independently by unsupervised hierarchical clustering. (B) Prognostic prediction for samples from subjects with data from ≥4 structures, with prognosis determined by sample metagene score. A single subject can be predicted to have high- or low-risk depending on which structure is analyzed. *CT normalized represents CT samples that underwent z-score normalization utilizing only the CT samples rather than all structure samples. (C) Kaplan–Meier survival analysis of all IvyGAP samples. (D) Kaplan–Meier analysis using a metagene score calculated applying CT samples, demonstrating a trend in survival stratification. (E) Kaplan–Meier analysis using a metagene score calculated applying only HBV samples, significantly and incorrectly stratified long versus short survivors. For survival analyses, metagene scores were used to risk stratify (poor prognosis: metagene score >0; good prognosis: metagene score <0).